Last reviewed · How we verify

Acthar Gel-Synthetic — Competitive Intelligence Brief

Acthar Gel-Synthetic (seractide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: seractide. Area: Nephrology.

marketed seractide Adrenocorticotropic hormone receptor Nephrology Live · refreshed every 30 min

Target snapshot

Acthar Gel-Synthetic (seractide) — Armour Pharm.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Acthar Gel-Synthetic TARGET seractide Armour Pharm marketed seractide Adrenocorticotropic hormone receptor 1978-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (seractide class)

  1. Armour Pharm · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acthar Gel-Synthetic — Competitive Intelligence Brief. https://druglandscape.com/ci/seractide. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: